DE102004043153B4 - Erfindung betreffend GLP-1 und Exendin - Google Patents

Erfindung betreffend GLP-1 und Exendin Download PDF

Info

Publication number
DE102004043153B4
DE102004043153B4 DE102004043153A DE102004043153A DE102004043153B4 DE 102004043153 B4 DE102004043153 B4 DE 102004043153B4 DE 102004043153 A DE102004043153 A DE 102004043153A DE 102004043153 A DE102004043153 A DE 102004043153A DE 102004043153 B4 DE102004043153 B4 DE 102004043153B4
Authority
DE
Germany
Prior art keywords
exendin
glp
amino acid
peptide derivatives
chimeric peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102004043153A
Other languages
German (de)
English (en)
Other versions
DE102004043153A1 (de
Inventor
Dr. Gotthardt Martin
Dr. Béhé Martin
Prof. Dr. Behr Thomas
Prof. Dr. Göke Burkhard J.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philipps-Universitaet Marburg 35037 Marburg De
Original Assignee
Philipps University of Marburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102004043153A priority Critical patent/DE102004043153B4/de
Application filed by Philipps University of Marburg filed Critical Philipps University of Marburg
Priority to MX2007002455A priority patent/MX2007002455A/es
Priority to PL10012756T priority patent/PL2301962T3/pl
Priority to KR1020077007577A priority patent/KR101237152B1/ko
Priority to CA002578252A priority patent/CA2578252A1/en
Priority to EP10012756.2A priority patent/EP2301962B1/de
Priority to CN2011101471272A priority patent/CN102304179A/zh
Priority to BRPI0515624-6A priority patent/BRPI0515624A/pt
Priority to PL08020703T priority patent/PL2070946T3/pl
Priority to RU2007112115/10A priority patent/RU2420536C2/ru
Priority to CN2005800297604A priority patent/CN101010340B/zh
Priority to CA2797666A priority patent/CA2797666A1/en
Priority to EP05778889A priority patent/EP1784422B1/de
Priority to CN201110114845.XA priority patent/CN102358752B/zh
Priority to JP2007528593A priority patent/JP5047795B2/ja
Priority to EP08020703.8A priority patent/EP2070946B1/de
Priority to AT05778889T priority patent/ATE486090T1/de
Priority to RU2010148447/10A priority patent/RU2489443C2/ru
Priority to HR20110061T priority patent/HRP20110061T1/hr
Priority to AU2005279537A priority patent/AU2005279537C1/en
Priority to PCT/DE2005/001503 priority patent/WO2006024275A2/de
Priority to DE502005010449T priority patent/DE502005010449D1/de
Publication of DE102004043153A1 publication Critical patent/DE102004043153A1/de
Priority to US11/712,978 priority patent/US8268781B2/en
Priority to NO20071592A priority patent/NO20071592L/no
Priority to RU2010148446/10A priority patent/RU2486197C2/ru
Priority to US13/593,866 priority patent/US20130095037A1/en
Application granted granted Critical
Publication of DE102004043153B4 publication Critical patent/DE102004043153B4/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
DE102004043153A 2004-09-03 2004-09-03 Erfindung betreffend GLP-1 und Exendin Expired - Fee Related DE102004043153B4 (de)

Priority Applications (26)

Application Number Priority Date Filing Date Title
DE102004043153A DE102004043153B4 (de) 2004-09-03 2004-09-03 Erfindung betreffend GLP-1 und Exendin
EP08020703.8A EP2070946B1 (de) 2004-09-03 2005-08-26 Erfindung betreffend GLP-1 und Exendin
KR1020077007577A KR101237152B1 (ko) 2004-09-03 2005-08-26 Ｇｌｐ-１ 및 엑센딘 관련 발명
CA002578252A CA2578252A1 (en) 2004-09-03 2005-08-26 Glp-1 and exendin related invention
EP10012756.2A EP2301962B1 (de) 2004-09-03 2005-08-26 Erfindung betreffend GLP-1 und Exendin
CN2011101471272A CN102304179A (zh) 2004-09-03 2005-08-26 与GLP-1和肠促胰岛素类似物(exendin)有关的发明
BRPI0515624-6A BRPI0515624A (pt) 2004-09-03 2005-08-26 invenção referente ao glp-1 e à exendina
PL08020703T PL2070946T3 (pl) 2004-09-03 2005-08-26 Wynalazek dotyczący GLP-1 i eksendyny
RU2007112115/10A RU2420536C2 (ru) 2004-09-03 2005-08-26 Пептидные производные эксендина-4
CN2005800297604A CN101010340B (zh) 2004-09-03 2005-08-26 与GLP-1和肠促胰岛素类似物（exendin)有关的发明
CA2797666A CA2797666A1 (en) 2004-09-03 2005-08-26 Peptide derivatives of exendin-3
EP05778889A EP1784422B1 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin
CN201110114845.XA CN102358752B (zh) 2004-09-03 2005-08-26 与GLP-1和肠促胰岛素类似物(exendin)有关的发明
JP2007528593A JP5047795B2 (ja) 2004-09-03 2005-08-26 Ｇｌｐ−１およびエキセンディンに関する発明
MX2007002455A MX2007002455A (es) 2004-09-03 2005-08-26 Invencion relacionada con glp-1 y exendida.
DE502005010449T DE502005010449D1 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin
AT05778889T ATE486090T1 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin
HR20110061T HRP20110061T1 (hr) 2004-09-03 2005-08-26 Izum koji se odnosi na glp-1 i eksendin
AU2005279537A AU2005279537C1 (en) 2004-09-03 2005-08-26 GLP-1 and exendin related invention
PCT/DE2005/001503 WO2006024275A2 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin
PL10012756T PL2301962T3 (pl) 2004-09-03 2005-08-26 Wynalazek dotyczący glp-1 i eksendyny
RU2010148447/10A RU2489443C2 (ru) 2004-09-03 2005-08-26 Изобретение, относящееся к glp-1 и эксендинам
US11/712,978 US8268781B2 (en) 2004-09-03 2007-03-02 Peptide derivatives of exendin-4
NO20071592A NO20071592L (no) 2004-09-03 2007-03-27 GLP-1 og exendinrelatert oppfinnelse
RU2010148446/10A RU2486197C2 (ru) 2004-09-03 2010-11-26 Изобретение, относящееся к glp-1 и эксендинам
US13/593,866 US20130095037A1 (en) 2004-09-03 2012-08-24 Peptide derivatives of exendin-4

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004043153A DE102004043153B4 (de) 2004-09-03 2004-09-03 Erfindung betreffend GLP-1 und Exendin

Publications (2)

Publication Number Publication Date
DE102004043153A1 DE102004043153A1 (de) 2006-03-23
DE102004043153B4 true DE102004043153B4 (de) 2013-11-21

Family

ID=35970651

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102004043153A Expired - Fee Related DE102004043153B4 (de) 2004-09-03 2004-09-03 Erfindung betreffend GLP-1 und Exendin
DE502005010449T Expired - Lifetime DE502005010449D1 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502005010449T Expired - Lifetime DE502005010449D1 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin

Country Status (16)

Country Link
US (2) US8268781B2 (enExample)
EP (3) EP2301962B1 (enExample)
JP (1) JP5047795B2 (enExample)
KR (1) KR101237152B1 (enExample)
CN (3) CN102358752B (enExample)
AT (1) ATE486090T1 (enExample)
AU (1) AU2005279537C1 (enExample)
BR (1) BRPI0515624A (enExample)
CA (2) CA2578252A1 (enExample)
DE (2) DE102004043153B4 (enExample)
HR (1) HRP20110061T1 (enExample)
MX (1) MX2007002455A (enExample)
NO (1) NO20071592L (enExample)
PL (2) PL2070946T3 (enExample)
RU (3) RU2489443C2 (enExample)
WO (1) WO2006024275A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017892A2 (en) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Novel compounds as glp-i agonists
EP3456340B1 (en) 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
JP4642920B2 (ja) * 2008-09-20 2011-03-02 国立大学法人京都大学 膵島イメージング用分子プローブ前駆体及びその使用
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
WO2010118034A2 (en) * 2009-04-06 2010-10-14 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
WO2011019020A1 (ja) * 2009-08-10 2011-02-17 国立大学法人京都大学 膵島イメージング用分子プローブ及びその前駆体、並びに、それらの使用
WO2011027584A1 (ja) * 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
JP5608867B2 (ja) * 2009-09-30 2014-10-15 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
KR101550006B1 (ko) 2009-12-10 2015-09-03 아크레이 가부시키가이샤 췌도 이미징용 분자 프로브 및 그 사용
CN101875700B (zh) * 2010-04-09 2012-09-26 无锡和邦生物科技有限公司 一种增加促胰岛素分泌肽融合蛋白生物活性的方法
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9278146B2 (en) 2010-10-08 2016-03-08 Kyoto University Peptide derivative and use of the same
WO2012121746A2 (en) * 2011-03-09 2012-09-13 The General Hospital Corporation Imaging beta cell mass
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8901484B2 (en) * 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) * 2012-04-27 2013-12-12 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
DE102014112747A1 (de) * 2014-09-04 2016-03-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
SI3389697T1 (sl) 2015-12-14 2021-02-26 Antaros Medical Ab Selektivni agonisti receptorja glukagona, ki obsegajo kelatni del za namene prikazovanja
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SMT202500120T1 (it) 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)
EP4171662A1 (en) 2020-03-31 2023-05-03 Antaros Medical AB Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1997046584A1 (de) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE120374T1 (de) * 1989-07-20 1995-04-15 Sandoz Ag Markierte polypeptidderivate.
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
EP1137667B1 (en) * 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
BR0010705A (pt) * 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
WO2001051078A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
WO2004037859A1 (ja) * 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1誘導体及びその経粘膜吸収型製剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1997046584A1 (de) * 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Datenbank PubMed, Zusammenfassung zu: KNUDSEN, L.B. [u.a.]: Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. (2000) 43 (9) 1664-9 *
Datenbank PubMed, Zusammenfassung zu: XIAO, Q. [u.a.]: Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry (06.03.2001) 40 (9) 2860-9 *

Also Published As

Publication number Publication date
PL2301962T3 (pl) 2014-05-30
WO2006024275A3 (de) 2006-11-30
KR20070093960A (ko) 2007-09-19
US20130095037A1 (en) 2013-04-18
EP2301962B1 (de) 2013-10-30
DE502005010449D1 (de) 2010-12-09
HRP20110061T1 (hr) 2011-02-28
US20090180953A1 (en) 2009-07-16
BRPI0515624A (pt) 2008-07-29
EP2070946A3 (de) 2009-09-09
EP2070946B1 (de) 2013-05-29
WO2006024275A2 (de) 2006-03-09
MX2007002455A (es) 2007-10-10
AU2005279537A1 (en) 2006-03-09
ATE486090T1 (de) 2010-11-15
RU2007112115A (ru) 2008-10-10
JP2008511557A (ja) 2008-04-17
US8268781B2 (en) 2012-09-18
KR101237152B1 (ko) 2013-03-04
JP5047795B2 (ja) 2012-10-10
RU2010148447A (ru) 2012-06-10
EP2301962A3 (de) 2011-11-02
AU2005279537C1 (en) 2012-07-05
RU2486197C2 (ru) 2013-06-27
RU2420536C2 (ru) 2011-06-10
RU2010148446A (ru) 2012-06-10
AU2005279537B2 (en) 2012-02-16
DE102004043153A1 (de) 2006-03-23
RU2489443C2 (ru) 2013-08-10
CN102358752A (zh) 2012-02-22
EP2070946A2 (de) 2009-06-17
CA2797666A1 (en) 2006-03-09
EP1784422A2 (de) 2007-05-16
CN101010340B (zh) 2012-11-28
CN101010340A (zh) 2007-08-01
CN102304179A (zh) 2012-01-04
NO20071592L (no) 2007-05-29
EP1784422B1 (de) 2010-10-27
CA2578252A1 (en) 2006-03-09
PL2070946T3 (pl) 2013-09-30
EP2301962A2 (de) 2011-03-30
CN102358752B (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
EP1784422B1 (de) Erfindung betreffend glp-1 und exendin
DE69605419T2 (de) Mehrfach-tyrosinierte somatostatin-analoga
DE69819478T2 (de) Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore
Kimura et al. Synthesis and biological evaluation of an 111In-labeled exendin-4 derivative as a single-photon emission computed tomography probe for imaging pancreatic β-cells
DE69230287T2 (de) Verbindungen und pharmazeutische zusammensetzungen zum nachweis und zur lokalisierung von geweben mit neurokinin-1-rezeptoren
AT405906B (de) Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
Mansi et al. Radiolabeled peptides for cancer imaging and therapy: from bench-to-bedside
DE60035787T2 (de) Neuropeptid-Y1-Rezeptor-bindende Verbindungen zur Behandlung und Diagnose von Krebserkrankungen
Obeid et al. Improving GRPR-targeting peptides for radiotheranostics application: insights from chelator modifications and α-methyl-L tryptophan substitution
Mi et al. Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with 18F-Al labeled Cys39-exendin-4
AU2012202855B2 (en) GLP-1 and exendin related invention
CN103275188B (zh) 放射性标记t140类多肽化合物及其制备方法和应用
Pujatti et al. Development of a new bombesin analog radiolabeled with lutetium-177: in vivo evaluation of the biological properties in balb-c mice
Chandra et al. Synthesis, radiolabeling and biological evaluation of a neutral tripeptide and its derivatives for potential nuclear medicine applications
TW202313120A (zh) 膽囊收縮素b受體靶向複合體及其造影劑
DE112011105133T5 (de) Octapeptid zur Herstellung von radiopharmazeutischen Mitteln, das auf dessen Basis hergestellte Arzneimittel und Diagnoseverfahren von Somatostatin-Rezeptor exprimierenden Tumoren
Linkowski Faintuch et al. Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis
DE102010026052A1 (de) 11C-markiertes Peptid zur Detektion eines krankhaften Gewebes, das einen IGF-Rezeptor exprimiert
Brom Development of a tracer to image pancreatic beta cells
DE102010026065A1 (de) 11C-markiertes Peptid zur Detektion eines Tumors, der einen Bombesin-Rezeptor exprimiert

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8122 Nonbinding interest in granting licences declared
8127 New person/name/address of the applicant

Owner name: PHILIPPS-UNIVERSITAET MARBURG, 35037 MARBURG, DE

R005 Application deemed withdrawn due to failure to request examination
R409 Internal rectification of the legal status completed
R074 Re-establishment allowed
R409 Internal rectification of the legal status completed
R012 Request for examination validly filed

Effective date: 20110829

R082 Change of representative

Representative=s name: PATENTANWAELTE OLBRICHT, BUCHHOLD, KEULERTZ PA, DE

R018 Grant decision by examination section/examining division
R020 Patent grant now final

Effective date: 20140222

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee